Seoul Pharma Co., Ltd (KOSDAQ:018680)

Seoul Pharma Statistics

Total Valuation

Seoul Pharma has a market cap or net worth of KRW 33.81 billion. The enterprise value is 41.26 billion.

Market Cap	33.81B
Enterprise Value	41.26B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Seoul Pharma has 11.66 million shares outstanding.

Current Share Class	11.66M
Shares Outstanding	11.66M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.07%
Owned by Institutions (%)	n/a
Float	4.72M

Valuation Ratios

The trailing PE ratio is 44.86.

PE Ratio	44.86
Forward PE	n/a
PS Ratio	0.65
PB Ratio	0.82
P/TBV Ratio	0.84
P/FCF Ratio	33.00
P/OCF Ratio	17.93
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 29.84, with an EV/FCF ratio of 40.27.

EV / Earnings	54.74
EV / Sales	0.79
EV / EBITDA	29.84
EV / EBIT	n/a
EV / FCF	40.27

Financial Position

The company has a current ratio of 2.28, with a Debt / Equity ratio of 0.42.

Current Ratio	2.28
Quick Ratio	1.51
Debt / Equity	0.42
Debt / EBITDA	12.58
Debt / FCF	16.98
Interest Coverage	-2.22

Financial Efficiency

Return on equity (ROE) is 1.86% and return on invested capital (ROIC) is -2.56%.

Return on Equity (ROE)	1.86%
Return on Assets (ROA)	-1.12%
Return on Invested Capital (ROIC)	-2.56%
Return on Capital Employed (ROCE)	-2.25%
Weighted Average Cost of Capital (WACC)	5.53%
Revenue Per Employee	303.19M
Profits Per Employee	4.38M
Employee Count	172
Asset Turnover	0.73
Inventory Turnover	1.75

Taxes

Income Tax	-122.07M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -12.20% in the last 52 weeks. The beta is 0.50, so Seoul Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.50
52-Week Price Change	-12.20%
50-Day Moving Average	2,753.60
200-Day Moving Average	3,065.48
Relative Strength Index (RSI)	66.87
Average Volume (20 Days)	6,440

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Seoul Pharma had revenue of KRW 52.15 billion and earned 753.64 million in profits.

Revenue	52.15B
Gross Profit	31.50B
Operating Income	-1.28B
Pretax Income	631.57M
Net Income	753.64M
EBITDA	1.38B
EBIT	-1.28B
Earnings Per Share (EPS)	n/a

Balance Sheet

The company has 9.95 billion in cash and 17.39 billion in debt, with a net cash position of -7.44 billion or -638.40 per share.

Cash & Cash Equivalents	9.95B
Total Debt	17.39B
Net Cash	-7.44B
Net Cash Per Share	-638.40
Equity (Book Value)	41.05B
Book Value Per Share	n/a
Working Capital	19.12B

Cash Flow

In the last 12 months, operating cash flow was 1.89 billion and capital expenditures -861.26 million, giving a free cash flow of 1.02 billion.

Operating Cash Flow	1.89B
Capital Expenditures	-861.26M
Depreciation & Amortization	2.66B
Net Borrowing	1.33B
Free Cash Flow	1.02B
FCF Per Share	87.87

Margins

Gross margin is 60.41%, with operating and profit margins of -2.45% and 1.45%.

Gross Margin	60.41%
Operating Margin	-2.45%
Pretax Margin	1.21%
Profit Margin	1.45%
EBITDA Margin	2.65%
EBIT Margin	-2.45%
FCF Margin	1.96%

Dividends & Yields

Seoul Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	2.23%
FCF Yield	3.03%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on April 12, 2004. It was a forward split with a ratio of 2.

Last Split Date	Apr 12, 2004
Split Type	Forward
Split Ratio	2

Scores

Seoul Pharma has an Altman Z-Score of 1.85 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.85
Piotroski F-Score	4